HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.

Abstract
We evaluated clinical activity of ⁹⁰Yttrium-ibritumomab (⁹⁰Y-ibritumomab) tiuxetan in extranodal marginal-zone lymphoma. From May 2004 to April 2011, 30 patients affected by relapsed/refractory marginal-zone lymphoma--arisen at any extranodal site--received ⁹⁰Y-ibritumomab tiuxetan at the activity of 0.4 mCi/kg. Median age was 57 years. At time of treatment, 13 out of 30 patients had disseminated disease (stage III/IV). All patients had received a previous treatment with a maximum of 7. Overall response rate was 90%: 23 patients achieved a complete response (77%); partial response occurred in 4 patients (13%), stable disease in 2 patients (7%) and 1 progression (3%). With a median follow-up of 5.3 years, median time to relapse was not reached; 2 patients relapsed after complete response; 18 out of 23 complete responses are still responders after >3 years, 12 of them after >5 years. ⁹⁰Y-ibritumomab tiuxetan seems to be active in patients with extranodal marginal-zone lymphoma relapsed/refractory to conventional treatment including radiotherapy. These results suggest that radioimmunotherapy could represent a possible option for the treatment in this subset of patients.
AuthorsAnna Vanazzi, Chiara Grana, Cristiano Crosta, Giancarlo Pruneri, Stefania Rizzo, Davide Radice, Antonello Pinto, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli
JournalHematological oncology (Hematol Oncol) Vol. 32 Issue 1 Pg. 10-5 (Mar 2014) ISSN: 1099-1069 [Electronic] England
PMID23696416 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 John Wiley & Sons, Ltd.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Yttrium Radioisotopes
  • Rituximab
  • ibritumomab tiuxetan
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Hematologic Diseases (chemically induced)
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, B-Cell, Marginal Zone (drug therapy, radiotherapy)
  • Male
  • Middle Aged
  • Prospective Studies
  • Radioimmunotherapy
  • Recurrence
  • Rituximab
  • Salvage Therapy
  • Stomach Neoplasms (drug therapy, radiotherapy)
  • Treatment Outcome
  • Yttrium Radioisotopes (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: